Data Points to Potential for Patient Centricity in Rare Disease Trial Success
For health policymakers at a national level, rare diseases are those affecting a tiny fraction of the population. Worldwide, however, this…
All articles by
-
-
Novel software solutions can ease transition in an age of clinical supply chain upheaval
The healthcare landscape faces turbulent times. Regulatory pressures, challenges around demand forecasting and an influx of novel therapies are heaping…
-
Pediatric research: how to fix a clinical trial system built for adults
Pediatric clinical trials are often designed according to templates established for adults. Yet there are notable differences between adults and…
-
Modular manufacturing: The key to unlocking mRNA expansion?
The evolving mRNA landscape has been marked by rapid advancements and a broadening scope of applications, primarily driven by the…
-
AI-powered orchestration: Bringing the benefits to personalized therapy
Cell and gene therapies represent a groundbreaking advancement in medical science, offering transformative opportunities for treating complex and previously untreatable…
-
The impact of drug pricing and reimbursement on the pharmaceutical industry
A recent survey for GlobalData’s “State of the Biopharmaceutical Industry 2025” report, conducted at the end of 2024, found drug…
-
Obesity therapies and the multi-indication momentum: how industry is responding
The obesity therapeutics market has gone from a standing start to the story of the year in biopharmaceuticals - and…
-
Reducing patient burden in rare disease trials: DCTs for increased patient centricity
Reducing patient burden in clinical trials – especially for rare diseases – is a key objective for drug developers. Decentralized…
-
Overcoming challenges in orphan drug development: From clinical trials to market
Developing treatments for rare diseases, known as orphan drugs, presents a range of unique challenges from the outset, from limited…
-
How collaborative partnerships are driving progress in transformative cell and gene therapies (CGTs)
Cell and gene therapies (CGTs) are currently at the heart of dynamic trends in the pharma sector. While oncology remains…